The ultrasound technology startup from Trondheim has raised 60MNOK from ProVenture, Investinor, CoFounder, PS Capital and other private investors.
We see the combination of Cimon Medical’s unique technology, impressive team, and the right partners in an exciting market as a good investment opportunity - says Geir Ove Kjesbu in ProVenture
Cimon Medical provides unique technology for continuous measurement of blood flow.
The company has its origin in the world leading ultrasound cluster in Doppler-ultrasound in Trondheim and is a part of the ultrasound group at NTNU and St. Olavs Hospital.
The target group for the company’s first product is premature and critically ill children.
Variations in blood flow in the brain increase the risk of brain damage in premature and critically ill newborns. Cimon Medical has developed NeoDoppler – a product that makes it possible to measure blood flow in the brain of these children over time. Until now there has been no good tool available for continuous surveillance of blood flow in children.